{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:11Z","timestamp":1786119131989,"version":"build-2736575974"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/icu.0b013e32831d1fc7","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T03:28:56Z","timestamp":1235359736000},"page":"110-115","source":"Crossref","is-referenced-by-count":5,"title":["Switching within glaucoma medication class"],"prefix":"10.1097","volume":"20","author":[{"given":"Simon K","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9394(01)01337-X","article-title":"A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data","volume":"133","author":"Nordmann","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","article-title":"Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients","volume":"112","author":"Konstas","year":"2005","journal-title":"Ophthalmology"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"A comparison of lantaoprost, bimatoprost, and travaprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/IJG.0b013e31815a3472","article-title":"Duration of IOP reduction with travoprost BAK-free solution","volume":"17","author":"Gross","year":"2008","journal-title":"J Glaucoma"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ophtha.2005.06.031","article-title":"Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization","volume":"112","author":"Law","year":"2005","journal-title":"Ophthalmology"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bjo.2006.110155","article-title":"Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract","volume":"91","author":"Cantor","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjp.0706989","article-title":"Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris","volume":"150","author":"Woodward","year":"2007","journal-title":"Br J Pharmacol"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1167\/iovs.07-0080","article-title":"Bimatoprost, prostamide activity, and conventional drainage","volume":"48","author":"Wan","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1167\/iovs.06-0896","article-title":"Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle","volume":"48","author":"Romano","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1167\/iovs.06-0100","article-title":"The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice","volume":"47","author":"Ota","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1167\/iovs.05-0723","article-title":"Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice","volume":"46","author":"Crowston","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.ijg.0000212214.18018.41","article-title":"An evaluation of the rate of nonresponders to latanoprost therapy","volume":"15","author":"Rossetti","year":"2006","journal-title":"J Glaucoma"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10384-005-0293-x","article-title":"Latanoprost nonresponders with open-angle glaucoma in the Japanese population","volume":"50","author":"Ikeda","year":"2006","journal-title":"Jpn J Ophthalmol"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ophtha.2007.03.025","article-title":"Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost","volume":"114","author":"Sakurai","year":"2007","journal-title":"Ophthalmology"},{"key":"R16-9-20210206","first-page":"49","article-title":"A novel single nucleotide polymorphism, IVS2-97A>T, in the prostaglandin F2alpha receptor gene was identified among the Malaysian patients with glaucoma","volume":"53","author":"Peng","year":"2007","journal-title":"Kobe J Med Sci"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02850299","article-title":"Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension","volume":"18","author":"Gandolfi","year":"2001","journal-title":"Adv Ther"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and lantanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-9394(02)01980-3","article-title":"Conjunctical hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost","volume":"135","author":"Stewart","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/bjo.87.8.956","article-title":"Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study","volume":"87","author":"Chiba","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ophtha.2003.11.013","article-title":"Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%","volume":"111","author":"McCarey","year":"2004","journal-title":"Ophthalmology"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","article-title":"Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy","volume":"16","author":"Lewis","year":"2007","journal-title":"J Glaucoma"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/archopht.1989.01070020378039","article-title":"Comparison of a noncardioselective ss-adrenergic blocker and a cardioselective blocker in reducing aqueous flow in humans","volume":"107","author":"Gaul","year":"1989","journal-title":"Arch Ophthalmol"},{"issue":"Suppl","key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0039-6257(94)90059-0","article-title":"Long-term effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma","volume":"38","author":"Collignon-Brach","year":"1994","journal-title":"Surv Ophthalmol"},{"key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archopht.1986.01050130056019","article-title":"Betaxolol versus timolol: a 6-month double-blind comparison","volume":"104","author":"Stewart","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1442-9071.1989.tb00553.x","article-title":"The significance of reactions to betaxolol reported by patients","volume":"17","author":"Brooks","year":"1989","journal-title":"Aust N Z J Ophthalmol"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9394(84)90450-1","article-title":"Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis","volume":"97","author":"Schoene","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0002-9394(86)90941-4","article-title":"Betaxolol in patients with glaucoma and asthma","volume":"101","author":"Van Buskirk","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9394(88)90828-8","article-title":"Long-term betaxolol therapy in glaucoma patients with pulmonary disease","volume":"106","author":"Weinreb","year":"1988","journal-title":"Am J Ophthalmol"},{"key":"R31-9-20210206","first-page":"80","article-title":"Acute episode of asthma following topical administration of betaxolol eye-drops","volume":"28","author":"Ananthanarayan","year":"1993","journal-title":"Can J Ophthalmol"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0002-9394(86)90157-1","article-title":"Respiratory difficulties with betaxolol","volume":"102","author":"Harris","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0002-9394(14)73203-9","article-title":"Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level","volume":"116","author":"Freedman","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0002-9394(14)70172-2","article-title":"Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group","volume":"123","author":"Netland","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0161-6420(93)31496-X","article-title":"Can the conc of timiolol or the freq of its administration be reduced?","volume":"100","author":"Letchinger","year":"1993","journal-title":"Ophthalmology"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/archopht.1980.01020041030004","article-title":"Evaluation of timolol in chronic open angle glaucoma: once a day versus twice a day","volume":"98","author":"Soll","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0420.1996.tb00062.x","article-title":"The IOP lowering effect of timolol in gel-forming solution [published correction appears in Acta Ophthalmol Scan 1996; 74:416]","volume":"74","author":"Rosenlund","year":"1996","journal-title":"Acta Ophthalmol Scand"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/archopht.1984.01040030429017","article-title":"Improving the therapeutic index of topically applied ocular drugs","volume":"102","author":"Zimmerman","year":"1984","journal-title":"Arch Ophthlamol"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archopht.116.11.1441","article-title":"Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans","volume":"116","author":"Schadlu","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/S0161-6420(99)90420-7","article-title":"Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%","volume":"106","author":"Barnes","year":"1999","journal-title":"Ophthalmology"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3928\/1542-8877-19990301-08","article-title":"Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevations following anterior segment laser procedures","volume":"30","author":"Chevrier","year":"1999","journal-title":"Ophthalmic Surg Lasers"},{"issue":"Suppl 1","key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0039-6257(96)82029-7","article-title":"Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension","volume":"41","author":"Schuman","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archopht.1997.01100160017002","article-title":"A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group","volume":"115","author":"Schuman","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R44-9-20210206","first-page":"1425","article-title":"Clinical pharmacology of adrenergic drugs","author":"Gieser","year":"1996"},{"key":"R45-9-20210206","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1006\/exer.1996.0267","article-title":"Mechanism of adrenergic induced allergy bioactivation and antigen formation","volume":"64","author":"Thompson","year":"1997","journal-title":"Exp Eye Res"},{"key":"R46-9-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00061198-200006000-00006","article-title":"Incidence of brimonidine allergy in patients previously allergic to a apraclonidine","volume":"9","author":"Williams","year":"2000","journal-title":"J Glaucoma"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/eye.1998.171","article-title":"Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy","volume":"12","author":"Gordon","year":"1998","journal-title":"Eye"},{"key":"R48-9-20210206","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9394(98)00450-4","article-title":"Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy","volume":"127","author":"Shin","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","article-title":"Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension","volume":"11","author":"Katz","year":"2002","journal-title":"J Glaucoma"},{"key":"R50-9-20210206","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archopht.1997.01100150047008","article-title":"Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans","volume":"115","author":"Maus","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R51-9-20210206","first-page":"209","article-title":"Ocular and systemic effects of acetazolamide in nephrectomized rabbits","volume":"23","author":"Friedman","year":"1982","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R52-9-20210206","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/exer.1993.1100","article-title":"A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion","volume":"57","author":"Brechue","year":"1993","journal-title":"Exp Eye Res"},{"key":"R53-9-20210206","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1034\/j.1600-0420.1998.760618.x","article-title":"A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group","volume":"76","author":"Hutzelmann","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"R54-9-20210206","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0161-6420(98)91421-X","article-title":"Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation","volume":"105","author":"Rosenberg","year":"1998","journal-title":"Ophthalmology"},{"key":"R55-9-20210206","first-page":"730","article-title":"The pharmacology of methazolamide in relation to the treatment of glaucoma","volume":"16","author":"Maren","year":"1977","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R56-9-20210206","first-page":"238","article-title":"Aqueous humor hydrodynamics","author":"Gabelt","year":"2003"},{"issue":"Suppl 2","key":"R57-9-20210206","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0039-6257(99)00111-3","article-title":"Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group","volume":"44","author":"Silver","year":"2000","journal-title":"Surv Ophthalmol"},{"key":"R58-9-20210206","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000050856","article-title":"Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide","volume":"215","author":"Seong","year":"2001","journal-title":"Ophthalmologica"},{"key":"R59-9-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9394(01)00974-6","article-title":"Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension","volume":"132","author":"Michaud","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R60-9-20210206","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/archopht.1982.01030040248007","article-title":"Duration of effect of pilocarpine gel","volume":"100","author":"March","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"R61-9-20210206","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/archopht.1975.01010020665001","article-title":"Pilocarpine Ocuserts. Long-term clinical trials and selected pharmacodynamics","volume":"93","author":"Quigley","year":"1975","journal-title":"Arch Ophthalmol"},{"key":"R62-9-20210206","first-page":"296","article-title":"An evaluation of the pilocarpine Ocusert","volume":"13","author":"Worthen","year":"1974","journal-title":"Invest Ophthalmol"},{"key":"R63-9-20210206","first-page":"206","article-title":"Management of chronic glaucoma with pilocarpine Ocuserts","volume":"97","author":"Hillman","year":"1977","journal-title":"Trans Ophthalmol Soc U K"},{"key":"R64-9-20210206","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/archopht.1976.03910040490004","article-title":"Visual effects of pilocarpine in glaucoma comparative study of administration by eyedrops or by ocular therapeutic systems","volume":"94","author":"Brown","year":"1976","journal-title":"Arch Ophthalmol"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e32831d1fc7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:34:30Z","timestamp":1786037670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-200903000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e32831d1fc7","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}